Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.41 |
| ▸ | STS | P08842 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | DTYMK | P23919 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21806017 | 0.86 | USP2 (0.45) | USP2SMN1; SMN2TLR8CHRM2CHRM4 | |
| SCHEMBL8242595 | 0.85 | USP2 (0.61) | USP2SMN1; SMN2TLR8CHRM2CHRM4 | |
| SCHEMBL22919673 | 0.82 | USP2 (0.47) | USP2SMN1; SMN2TLR8CHRM2CHRM4 | |
| SCHEMBL2074818 | 0.82 | USP2 (0.44) | USP2SMN1; SMN2TLR8CHRM2CHRM4 | |
| SCHEMBL20873847 | 0.82 | USP2 (0.53) | USP2SMN1; SMN2TLR8CHRM2CHRM4 | |
| SCHEMBL1901473 | 0.81 | TLR8 (0.45) | USP2SMN1; SMN2TLR8CHRM2CHRM4 | |
| SCHEMBL15273424 | 0.81 | USP2 (0.46) | USP2SMN1; SMN2TLR8CHRM2CHRM4 | |
| SCHEMBL2006368 | 0.81 | ACKR3 (0.47) | USP2SMN1; SMN2TLR8CHRM2CHRM4 | |
| SCHEMBL31457405 | 0.81 | TLR8 (0.45) | USP2SMN1; SMN2TLR8CHRM2CHRM4 | |
| SCHEMBL31457404 | 0.81 | TLR8 (0.45) | USP2SMN1; SMN2TLR8CHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023097189-A1 | AMPK ACTIVATORS | KALLYOPE, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| WO-2023097187-A1 | AMPK ACTIVATORS | KALLYOPE, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| WO-2013149362-A1 | 1-(DIHYDRONAPHTHALENYL)PYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR 1 ANTAGONISTS | GLAXOSMITHKLINE LLC (US) | 2013-10-10 | — | — | WO | disclosed |
| WO-2013149362-A1 | 1-(DIHYDRONAPHTHALENYL)PYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR 1 ANTAGONISTS | GLAXOSMITHKLINE LLC (US) | 2013-10-10 | — | — | WO | disclosed |
| EP-2162454-B1 | IMIDAZOPYRIDINE KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2013-01-02 | — | — | EP | disclosed |
| EP-2162454-B1 | IMIDAZOPYRIDINE KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2013-01-02 | — | — | EP | disclosed |
| CN-101370799-B | Cis-4, 5-diaryl-2-heterocycle-imidazolines as MDM2 inhibitors | HOFFMANN LA ROCHE | 2012-09-05 | — | — | CN | disclosed |
| CN-1953965-B | Novel cis-imidazolines | HOFFMANN LA ROCHE | 2012-07-04 | — | — | CN | disclosed |
| EP-2406234-A1 | THIAZOLE SULFONAMIDE AND OXAZOLE SULFONAMIDE KINASE INHIBITORS | GlaxoSmithKline LLC (US) | 2012-01-18 | — | — | EP | disclosed |
| US-8093239-B2 | Imidazopyridine kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2012-01-10 | — | — | US | disclosed |
| US-20070167437-A1 | Cis-imidazolines | FOTOUHI NADER | 2007-07-19 | — | — | US | disclosed |
| CN-1953965-A | Novel cis-imidazolines | HOFFMANN LA ROCHE (CH) | 2007-04-25 | — | — | CN | disclosed |
| EP-1758868-A1 | NOVEL CIS-IMIDAZOLINES | F. Hoffmann-La Roche AG (CH) | 2007-03-07 | — | — | EP | disclosed |
| EP-1753727-A1 | NOVEL CIS-IMIDAZOLINES | F.HOFFMANN-LA ROCHE AG (CH) | 2007-02-21 | — | — | EP | disclosed |
| WO-2006097261-A1 | CIS-2,4,5-TRIARYL-IMIDAZOLINES AND THEIR USE AS ANTI-CANCER MEDICAMENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-09-21 | — | — | WO | disclosed |
| US-20060211693-A1 | Cis-imidazolines | FOTOUHI NADER | 2006-09-21 | — | — | US | disclosed |
| WO-2005123691-A1 | NOVEL CIS-IMIDAZOLINES | F-HOFFMANN-LA ROCHE AG (CH) | 2005-12-29 | — | — | WO | disclosed |
| US-20050288287-A1 | Chiral cis-imidazolines | FOTOUHI NADER | 2005-12-29 | — | — | US | disclosed |
| US-20050282803-A1 | CIS-imidazolines | HALEY GREGORY J | 2005-12-22 | — | — | US | disclosed |
| WO-2005110996-A1 | NOVEL CIS-IMIDAZOLINES | F.HOFFMANN-LA ROCHE AG (CH) | 2005-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282803-A1 | CIS-imidazolines | PPIP5K2, PIN1, CCNI | USP2 4549/4885SMN1; SMN2 2154/4885TLR8 3898/4885 |
| US-20060211693-A1 | Cis-imidazolines | TP53, MDM2, CDC25C | USP2 1372/4885SMN1; SMN2 2851/4885TLR8 4679/4885 |
| US-20050288287-A1 | Chiral cis-imidazolines | TP53, MDM2, TP53BP1 | USP2 670/4885SMN1; SMN2 3320/4885TLR8 4729/4885 |
| US-20070167437-A1 | Cis-imidazolines | CCNI, CCNE1, CCNA1 | USP2 4325/4885SMN1; SMN2 1749/4885TLR8 4535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.